Business
Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE Study: First Prospective, Multi-Center, Multi-Specialty Study on Lumbar Interlaminar Fusion 
CARLSBAD, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or ...
About this update from Aurora Spine Corp.
[{"type":"text","content":"Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE Study: First Prospective, Multi-Center, Multi-Specialty Study on Lumbar Interlaminar Fusion \n\n\n\n CARLSBAD, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (\"Aurora Spine\" or the \"Company\") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the completion of patient enrollment in its REFINE study of its ZIP™ Interspinous Fixation device for patients suffering from back pain due to symptomatic degenerative disc disease . This prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care.\n \n\n\n\n The REFINE study, designed to bridge the gap between conservative treatments and more invasive surgical options, has successfully enrolled its full cohort of patients across multiple centers in the United States. Data from this pioneering study will be published out to one year, with a subsequent cohort publication extending to two years, offering robust, long-term insights into patient outcomes. The results will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025, spotlighting Aurora Spine’s commitment to evidence-based innovation.\n \n\n\n\n “This study represents a leap forward in how we understand and treat lumbar spinal conditions,” said Dr. Steven Falowski, co-Principal Investigator and Functional Neurosurgeon at Argires-Marotti Neurosurgical Associates of Lancaster, PA. “The data we’ve gathered is critical, it’s not just numbers, it’s the foundation for improving patient lives. The REFINE study will provide the highest level of scientific evidence to guide clinical decision-making and elevate the standard of care.”\n \n\n\n\n Dr. Steven Anagnost, an orthopedic surgeon at Oklahoma Spine and Musculoskeletal Medicine, echoed this optimism: “The impact of the REFINE study cannot be overstated. As an orthopedic surgeon, I see firsthand the need for reliable, minimally invasive solutions. This trial’s comprehensive, multi-specialty approach will shape...